BNTCNasdaqPharmaceutical PreparationsFiscal year ends June 30
Benitec Biopharma Inc.
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 14, 2026
$8.36+0.25 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $413.29M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2026
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | -91.8% | -33.2% | |
| Return on assets | – | -84.2% | -32.3% | |
| Current ratio | – | 15.05 | 34.00 | |
| Capex to revenue | – | 374.6% | – | |
| Diluted shares | – | 19M | 47M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Benitec Biopharma generated $93.42M from operations and spent $316.00K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$93.42M
Used
$316.00K
Capital expenditure$316.00K100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-26082.7%
×Asset turnover0.01×
×Equity multiplier3.38×
=Return on equity, FY2023-1268.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -26082.7% | 0.01× | 3.38× | -1268.6% |
| FY2022 | -24942.5% | 0.01× | 1.19× | -159.1% |
| FY2021 | -23528.8% | 0.00× | 1.09× | -91.8% |
| FY2020 | -8111.8% | 0.01× | 1.15× | -61.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 6 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$45.55M
- Cash generatingOperating cash flow above zero-$16.52M
- Return on assets improvedROA up on the prior year-72.6% → -45.7%
- Earnings backed by cashOperating cash flow above net income-$16.52M vs -$45.55M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose54.67 → 34.00
- No dilutionShare count did not rise36M → 47M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –